Citigroup
PBLS

Citigroup’s Parabilis Medicines Inc PBLS Stock Holding History

Citigroup’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.2K Buy
+1,869
New +$51.6K ﹤0.01% 4968

Other funds holding PBLS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
BIA
Bell Investment Advisors Oakland, California $681M AUM 18.36% 1-Year Est. Return

Citigroup's PBLS Position: Q2 2026 in Review

Citigroup opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 1,869 shares worth $51.2K. The stake represents ﹤0.01% of the portfolio and ranks #4968 among its holdings.

17 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

  • Citigroup held 1,869 shares of Parabilis Medicines Inc worth $51.2K as of Q2 2026.
  • Parabilis Medicines Inc was a new Citigroup position in Q2 2026.
  • Parabilis Medicines Inc made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4968 holding.
  • 17 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.